デメチルクロルテトラサイクリン塩酸塩

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H315：皮膚刺激

  H319：強い眼刺激

  H335：呼吸器への刺激のおそれ

  H341：遺伝性疾患のおそれの疑い

• 注意書き

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

  P301+P312：飲み込んだ場合：気分が悪い時は医師に連絡する こと。

  P305+P351+P338：眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

  P308+P313：暴露または暴露の懸念がある場合：医師の診断/手当てを 受けること。

デメチルクロルテトラサイクリン塩酸塩 価格

デメチルクロルテトラサイクリン塩酸塩 化学特性,用途語,生産方法

• 外観

  黄色～緑黄色, 結晶性粉末～粉末

• 溶解性

  水及びエタノールに溶け、アセトンにほとんど溶けない。

• 効能

  抗生物質, タンパク質合成阻害薬

• 商品名

  レダマイシン (ポーラファルマ)

• 使用上の注意

  アルゴン封入

• 説明

  Demeclocycline lacks the C-6-methyl of tetracycline and is produced by a genetically altered strain of Streptomyces aureofaciens. Because it is a secondary alcohol, it is more chemically stable than tetracycline against dehydration. Food and milk co-consumption decrease absorption by half, although it is 60 to 80% absorbed by fasting adults. It is the tetracycline most highly associated with phototoxicity and has been shown to produce dose-dependent, reversible diabetes insipidus with extended use.

• 化学的特性

  Yellow Solid

• 使用

  Demeclocycline hydrochloride is a salt prepared from demeclocycline taking advantage of the basic dimethylamino group which protonates and readily forms a salt in hydrochloric acid solutions. The hydrochloride is the preferred formulation for pharmaceutical applications. Like all tetracyclines, demeclocycline shows broad spectrum antibacterial and antiprotozoan activity and acts by binding to the 30S and 50S ribosomal subunits, blocking protein synthesis.

• 定義

  ChEBI: The hydrochloride salt of demeclocycline. A tetracycline antibiotic, it is used (mainly as the hydrochloride) for the treatment of Lyme disease, acne and bronchitis, as well as for hyponatraemia (low blood sodium concentration) due to the syndrome of inapp opriate antidiuretic hormone (SIADH) where fluid restriction alone has been ineffective.

• 抗菌性

  Occasional strains of viridans streptococci, N. gonorrhoeae and H. influenzae are more susceptible than to tetracycline. It is the most active tetracycline against Brucella spp.

• 一般的な説明

  Demeclocycline, 7-chloro-6-demethyltetracycline (Declomycin),was isolated in 1957 by McCormick et al. from amutant strain of S. aureofaciens. Chemically, it is 7-chloro-4-(dimethylamino)1,4,4a,5,5a,6, 11, 12a-octahydro-3, 6, 10, 12,12a-pentahydroxy1, 11-dioxo2-naphthacenecarboxamide.Thus, it differs from chlortetracycline only in the absence ofthe methyl group on C-6.
  Demeclocycline is a yellow, crystalline powder that isodorless and bitter. It is sparingly soluble in water. A 1% solutionhas a pH of about 4.8. It has an antibiotic spectrumlike that of other tetracyclines, but it is slightly more activethan the others against most of the microorganisms forwhich they are used. This, together with its slower rate ofelimination through the kidneys, makes demeclocycline aseffective as the other tetracyclines, at about three fifths ofthe dose. Like the other tetracyclines, it may cause infrequentphotosensitivity reactions that produce erythema afterexposure to sunlight. Demeclocycline may produce this reactionsomewhat more frequently than the other tetracyclines.The incidence of discoloration and mottling of theteeth in youths from demeclocycline appears to be as low asthat from other tetracyclines.

• 応用例（製薬）

  6-Demethyl-7-chlortetracycline. A fermentation product of a mutant strain of Streptomyces aureofaciens formulated as the hydrochloride for oral administration.

• 薬物動態学

  Oral absorption： 60–70%
  C_max 300 mg oral：2 mg/L after 3–6 h
  Plasma half-life：c.12 h
  Volume of distribution：c.1.7 L/kg
  Plasma protein binding：90%
  Absorption
  It is promptly yet incompletely absorbed by mouth, giving mean peak plasma levels after a single dose that are slightly higher than those produced by oxytetracycline and chlortetracycline, but lower than those achieved by tetracycline. However, with repeat dosing, steady-state concentrations exceed those for tetracycline. Simultaneous administration of antacids markedly depresses blood levels.
  Distribution and excretion
  It is widely distributed, achieving concentrations in pleural exudates
  similar to those of blood. CSF penetration is poor, especially in the absence of inflammation. Biliary concentrations
  are 20–30 times higher than those of plasma, and 40–50% of the drug can be recovered from feces. The other route of elimination is via glomerular filtration without reabsorption and accumulation occurs in renal failure.

• 臨床応用

  It has been extensively used in the management of the syndrome of inappropriate ADH secretion in a dose of at least 1.2 g per day; therapeutic response may take several days, but is superior to that of lithium. It has also found occasional use in patients with water retention as a result of congestive cardiac failure and in those with alcoholic cirrhosis and water and electrolyte retention.

• 副作用

  Untoward reactions, notably gastrointestinal intolerance, are generally those typical of the group. Occasional patients develop transient steatorrhea.
  Of particular note is the occurrence of nephrogenic diabetes insipidus with development of vasopressin-resistant polyuria. The effect is dose dependent and occurs with daily doses in excess of 1.2 g. The drug inhibits activation of adenylate cyclase and protein kinase, which are both important in the interaction of antidiuretic hormone (ADH) with receptors within the renal tubule, thus decreasing the effect of ADH on the kidney. As a result, it has found a place in the treatment of inappropriate ADH secretion.
  Renal failure may occur, particularly if prescribed for those with advanced liver cirrhosis. The mechanism is uncertain but may in part be related to the antianabolic effect of the tetracyclines as well as a direct toxic effect.
  Photosensitivity may be severe and accompanied by vesiculation, edema and onycholysis. It is largely restricted to exposed skin; patients should avoid prolonged exposure to sunlight.

• 純化方法

  Crystallise the salt from EtOH/Et2O or H2O and dry it in air [McCormick et al. J Am Chem Soc 79 4561 1957, Dobrynin et al. Tetrahedron Lett 901 1962]. [Beilstein 14 IV 2625.]

デメチルクロルテトラサイクリン塩酸塩 上流と下流の製品情報

デメチルクロルテトラサイクリン塩酸塩 生産企業

Global(319)Suppliers

64-73-3, デメチルクロルテトラサイクリン塩酸塩 キーワード